×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Actinium Pharmaceuticals' (ATNM) “Buy” Rating Reaffirmed at HC Wainwright
Defense World
Read Actinium Pharmaceuticals' (ATNM) “Buy” Rating Reaffirmed at HC Wainwright at Defense World.
7 hours ago
Will Actinium Be Big Pharma's Next Radiopharmaceuticals Acquisition?
In Vivo
With big pharma on a radiopharmaceuticals buying spree, New York-based Actinium Pharmaceuticals has been pointed to as the next potential...
2 days ago
Analysts Set Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Target Price at $25.60
MarketBeat
Shares of Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM - Get Free Report) have received an average rating of "Buy" from the six ratings...
17 hours ago
Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron ...
PR Newswire
Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy...
2 months ago
Actinium Pharmaceuticals Promising AML Treatment With Targeted Radiotherapies (ATNM)
Seeking Alpha
Actinium Pharmaceuticals is a late-stage biopharmaceutical company focused on developing radiotherapies for AML patients.
1 week ago
Actinium Pharmaceuticals announces presentation on Iomab-B survival outcomes - TipRanks.com
Tipranks
Actinium Pharmaceuticals “announced that results from the Phase 3 SIERRA trial of Iomab-B have been accepted for an oral presentation and poster...
6 days ago
ATNM Stock Quote Price and Forecast
CNN
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies.
1 month ago
Nuclear Medicine Is Big Pharma's New Target in Cancer Race
Bloomberg
As pharma giants spend billions on acquisitions of startups developing new ways to harness radiation in the fight against cancer,...
1 month ago
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active ...
The Victoria Advocate
Active relapsed or refractory AML patients 65+ years receiving an Iomab-B led Bone Marrow Transplant (BMT) achieved significant improvement...
2 months ago
Actinium Pharma shares gets Overweight rating By Investing.com
Investing.com
Tuesday - Actinium Pharmaceuticals, Inc. (NYSE:ATNM) received a new Overweight rating from Stephens, accompanied by a $25.00 price target.
1 week ago